Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG)

Reyes-Botero German; Cartalat-Carel Stephanie; Chinot Olivier L.; Barrie Maryline; Taillandier Luc; Beauchesne Patrick; Catry-Thomas Isabelle; Barriere Jerome; Guillamo Jean-Sebastien; Fabbro Michel; Frappaz Didier; Benouaich-Amiel Alexandra; Le Rhun Emilie; Campello Chantal; Tennevet Isabelle; Ghiringhelli Francois; Tanguy Marie-Laure; Mokhtari Karima; Honnorat Jerome; Delattre Jean-Yves

首页> 外文期刊>The oncologist >Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG)

【24h】

Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG)

机译：替莫唑胺加上老年患有新诊断的胶质母细胞瘤患者的贝伐单抗和性能状况不佳：ANOCEF期二期试验（ATAG）

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background. The optimal treatment of glioblastoma multiforme (GBM) in patients aged = 70 years with a Karnofsky performance status (KPS) 70 is not established. This clinical trial evaluated the efficacy and safety of upfront temozolomide (TMZ) and bevacizumab (Bev) in patients aged = 70 years and a KPS 70.

机译：背景。较低患者胶质母细胞瘤多形（GBM）的最佳处理; = 70年，Karnofsky性能状态（KPS）＆lt 70岁。该临床试验评估了患者上前粒粒子（TMZ）和Bevacizumab（Bev）的疗效和安全性。= 70岁和KPS＆ 70。

著录项

来源
《The oncologist》 |2018年第5期|共8页
作者
Reyes-Botero German; Cartalat-Carel Stephanie; Chinot Olivier L.; Barrie Maryline; Taillandier Luc; Beauchesne Patrick; Catry-Thomas Isabelle; Barriere Jerome; Guillamo Jean-Sebastien; Fabbro Michel; Frappaz Didier; Benouaich-Amiel Alexandra; Le Rhun Emilie; Campello Chantal; Tennevet Isabelle; Ghiringhelli Francois; Tanguy Marie-Laure; Mokhtari Karima; Honnorat Jerome; Delattre Jean-Yves;
展开▼
作者单位

Grp Hosp Pitie Salpetriere Serv Neurol Mazarin 2 47-83 Blvd Hop F-75013 Paris France;

Hosp Civils Lyon Dept Neurooncol Hop Neurol Lyon France;

Aix Marseille Univ CHU Timone AP HM Serv Neurooncol Marseille France;

Aix Marseille Univ CHU Timone AP HM Serv Neurooncol Marseille France;

CHU Nancy Nancy France;

CHU Nancy Nancy France;

Hop St Andre CHU Bordeaux France;

Ctr Antoine Lacassagne Nice France;

CHU Caen Caen France;

Inst Reg Canc Montpellier Montpellier France;

Ctr Leon Berard Lyon France;

CHU Rangueil Toulouse France;

Ctr Oscar Lambret Lille France;

CHU Nimes Nimes France;

Ctr Henri Becquerel CLCC Rouen France;

Georges Francois Leclerc Canc Ctr Dijon France;

CHU Pitie Salpetriere AP HP Paris France;

CHU Pitie Salpetriere AP HP Paris France;

Hosp Civils Lyon Dept Neurooncol Hop Neurol Lyon France;

Grp Hosp Pitie Salpetriere Serv Neurol Mazarin 2 47-83 Blvd Hop F-75013 Paris France;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG) [J] . Germ??n Reyesa??Botero, St??phanie Cartalata??Carel, Olivier L. Chinot, The oncologist . 2018,第5期

机译：替莫唑胺加贝伐珠单抗治疗新诊断成胶质母细胞瘤老年患者的不良表现：ANOCEF II期临床试验（ATAG）
2. Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG) [J] . Reyes-Botero German, Cartalat-Carel Stephanie, Chinot Olivier L., The oncologist . 2018,第5期

机译：替莫唑胺加上老年患有新诊断的胶质母细胞瘤患者的贝伐单抗和性能状况不佳：ANOCEF期二期试验（ATAG）
3. Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: An ANOCEF phase II trial [J] . Pérez-LarrayaJ.G., DucrayF., ChinotO., Journal of Clinical Oncology . 2011,第22期

机译：替莫唑胺在新诊断成胶质母细胞瘤和低效状态的老年患者中的应用：ANOCEF II期临床
4. RISK-ADAPTED INTRAVENOUS MELPHALAN WITH ADJUVANT THALIDOMIDE AND DEXAMETHASONE FOR NEWLY DIAGNOSED UNTREATED PATIENTS WITH SYSTEMIC AL AMYLOIDOSIS: INTERIM REPORT OF A PHASE II TRIAL [C] . RL Comenzo, P Zhou, L Reich, International Symposium on Amyloidosis . 2005

机译：风险适应的静脉内莫尔甘蔗用佐剂沙利度胺和地塞米松，用于新诊断的未经治疗的全身淀粉样蛋白症患者：II期试验的中期报告
5. A phase I study of vincristine, escalating doses of irinotecan, temozolomide and bevacizumab (VIT-B) in pediatric and adolescent patients with recurrent or refractory solid tumors of non-hematopoietic origin [D] . Venkatramani, Rajkumar. 2010

机译：长春新碱，伊非替康，替莫唑胺和贝伐单抗（VIT-B）逐步剂量在患有非造血源性复发或难治性实体瘤的儿童和青少年患者中的I期研究
6. Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG) [O] . Germán Reyes‐Botero, *, Stéphanie Cartalat‐Carel, 2018

机译：替莫唑胺加贝伐珠单抗治疗新诊断成胶质母细胞瘤的老年患者的不良表现：ANOCEF II期试验（ATAG）
7. Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG) [O] . Germán Reyes‐Botero, Stéphanie Cartalat‐Carel, Olivier L. Chinot, 2018

机译：替莫唑胺类加上老年患有新诊断的胶质母细胞瘤和性能状况不佳的患者：ANOCEF期间试验（ATAG）

Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG)

摘要

著录项

相似文献

相关主题

期刊订阅